Shorter Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia: The Experience of the Prospective, Randomized Brazilian GBTLI ALL-93 Protocol by Silvia R. Brandalise et al.
October 2016 | Volume 4 | Article 1101
Original research
published: 17 October 2016
doi: 10.3389/fped.2016.00110
Frontiers in Pediatrics | www.frontiersin.org
Edited by: 
Alex Kentsis, 
Memorial Sloan Kettering Cancer 
Center, USA
Reviewed by: 
Peter Michael Gordon, 
University of Minnesota, USA  
Jessica Carolyn Shand, 
University of Rochester Medical 
Center, USA
*Correspondence:
Silvia R. Brandalise 
silvia@boldrini.org.br
Specialty section: 
This article was submitted to 
Pediatric Hematology and 
Hematological Malignancies, 
a section of the journal 
Frontiers in Pediatrics
Received: 21 July 2016
Accepted: 26 September 2016
Published: 17 October 2016
Citation: 
Brandalise SR, Viana MB, 
Pinheiro VRP, Mendonça N, 
Lopes LF, Pereira WV, Lee MLM, 
Pontes EM, Zouain-Figueiredo GP, 
Azevedo ACAC, Pimentel N, 
Fernandes MZ, Oliveira HM, 
Vianna SR, Scrideli CA, Werneck FA, 
Álvares MN, Boldrini É, Loggetto SR, 
Bruniera P, Mastellaro MJ, Souza EM, 
Araújo RA, Bandeira F, Tan DM, 
Carvalho NA and Salgado MAS 
(2016) Shorter Maintenance Therapy 
in Childhood Acute Lymphoblastic 
Leukemia: The Experience of the 
Prospective, Randomized Brazilian 
GBTLI ALL-93 Protocol. 
Front. Pediatr. 4:110. 
doi: 10.3389/fped.2016.00110
shorter Maintenance Therapy in 
childhood acute lymphoblastic 
leukemia: The experience of the 
Prospective, randomized Brazilian
gBTli all-93 Protocol
 
Silvia R. Brandalise1*, Marcos B. Viana2, Vitória R. P. Pinheiro1, Núbia Mendonça3,  
Luiz F. Lopes4, Waldir V. Pereira5, Maria L. M. Lee6, Elitânia M. Pontes7,  
Gláucia P. Zouain-Figueiredo8, Alita C. A. C. Azevedo9, Nilma Pimentel10,  
Maria Z. Fernandes9, Hilda M. Oliveira11, Sônia R. Vianna12, Carlos A. Scrideli13,  
Fernando A. Werneck14, Maria N. Álvares15, Érica Boldrini16, Sandra R. Loggetto17,  
Paula Bruniera18, Maria J. Mastellaro19, Eni M. Souza20, Rogério A. Araújo21, 
Flávia Bandeira22, Doralice M. Tan3, Nelson A. Carvalho23 and Maria A. S. Salgado1
1Boldrini Children’s Center, Campinas, Brazil, 2 Federal University of Minas Gerais, Belo Horizonte, Brazil, 3Onco Bahia 
Hospital, Salvador, Brazil, 4A. C. Camargo Hospital, São Paulo, Brazil, 5Santa Maria University, Santa Maria, Brazil, 
6GRAACC, São Paulo, Brazil, 7GRUPO Hospital, São José, Brazil, 8Nossa Senhora da Glória Hospital, Rio de Janeiro, Brazil, 
9Varela Santiago Children’s Hospital, Natal, Brazil, 10Erick Loeff Hospital, Salvador, Brazil, 11Felicio Rocho Hospital, Belo 
Horizonte, Brazil, 12State Public Hospital, São Paulo, Brazil, 13Clinic Hospital, Ribeirão Preto, Brazil, 14State Public Hospital, 
Rio de Janeiro, Brazil, 15Center Chemotherapy LTD., Belo Horizonte, Brazil, 16São Judas Tadeu Hospital, Barretos, Brazil, 
17Hematology Center, São Paulo, Brazil, 18Santa Casa, São Paulo, Brazil, 19CLEMED Clinic, Jundiai, Brazil, 20Ana Costa 
Hospital, Santos, Brazil, 21Cancer Hospital, Uberlândia, Brazil, 22Hematology and Hemotherapy Foundation (HEMOPE), 
Recife, Brazil, 23St. Joachim’s Portuguese Charity Hospital, São Paulo, Brazil
aim: Maintenance therapy is an important phase of the childhood ALL treatment, requir-
ing 2-year long therapy adherence of the patients and families. Weekly methotrexate 
with daily 6-mercaptopurine (6MP) constitutes the backbone of maintenance therapy. 
Reduction in the maintenance therapy could overweight problems related with poverty 
of children with ALL living in limited-income countries (LIC).
Objective: To compare, prospectively, the EFS rates of children with ALL treated 
according to two maintenance regimens: 18 vs. 24 months duration.
Materials and methods: From October 1993 to September 1999, 867 consecu-
tive untreated ALL patients <18 years of age were treated according to the Brazilian 
Cooperative Group for Childhood ALL Treatment (GBTLI) ALL-93 protocol. Risk classifi-
cation was based exclusively on patient’s age and leukocyte count (NCI risk group) and 
clinical extra medullary involvement of the disease. Data were analyzed by the intention-
to-treat approach.
results: Fourteen patients (1.6%) were excluded: wrong diagnosis (n = 7) and previ-
ous corticosteroid (n = 7). Of the 853 eligible patients, 421 were randomly allocated, 
at study enrollment, to receive 18-month (group 1) and 432 to receive 24-month 
(group 2) maintenance therapy. Complete remission rate was achieved in 96% of 
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inTrODUcTiOn
The last four decades have witnessed tremendous improvement on 
the survival rates of children suffering from acute lymphoblastic 
leukemia (ALL), which was made possible, thanks to the promi-
nent effort of various multicenter Cooperative ALL Treatment 
Groups. Different immunophenotype and genetic subgroups of 
ALL were identified, which in conjunction with the evaluation of 
the patient’s initial response to therapy, through minimal residual 
disease (MRD) quantification at different time-points, have 
allowed the development of tailored treatment protocols by all the 
Cooperative Groups. Today, in the best contemporary treatment 
protocols, survival rates for childhood ALL patients are above 
85%. Approximately one-third of all deaths are due to treatment 
toxicity, even with the high-quality supportive care available in 
high-income countries (1, 2).
However, for children with ALL living in low- and middle-
income countries, survival rates are yet significantly lower than 
those attained in high-income areas of the world (3, 4). Several 
factors contribute to the inferior survival results, including lower 
socioeconomic status and education, limited access to special-
ized centers, reduced offer of genetic, immunophenotyping and 
molecular biology exams, and shortage of some chemotherapeu-
tic drugs. All these factors are interconnected in a complex way 
and contribute to failure of adherence to treatment, thus playing 
an important role in clinical practice.
Maintenance therapy is as important as the more intensive and 
toxic earlier treatment phases, and often more challenging (5). 
Treatment of childhood ALL requires a prolonged maintenance 
phase that relies on self- or parent-administered daily antime-
tabolite chemotherapy given over a period of about 2 years (6–9). 
A systematic review of 42 randomized studies with 12,000 child-
hood ALL cases indicated that longer maintenance therapy gave 
a slightly lower risk of relapse but with no difference in survival 
due to a higher risk of death in remission (10). Lack of adherence, 
as well as associated infections, are important issues associated to 
unsuccessful maintenance treatment. We reasoned that a shorter 
maintenance therapy could be advantageous for the patients and 
their families, both by favoring adherence and by shortening the 
immunosuppression period. In the Brazilian Cooperative Group 
for Childhood ALL Treatment ALL-93 protocol (GBTLI ALL-
93), the treatment schema included the induction (phase 1 and 
2), consolidation and an intensification phase, followed by 18- or 
24-month maintenance therapy.
Objective
The primary aim of this study was to compare, according to the 
intention-to-treat, the event-free survival (EFS) rates in children 
with ALL randomized at diagnosis, to receive a maintenance 
therapy regimen of 18 vs. 24 months duration.
MaTerials anD MeThODs
Patients
Eight hundred and sixty seven consecutive patients with newly 
diagnosed ALL, aged 0–18 years, who received no previous glu-
cocorticoid treatment, were enrolled in the clinical trial GBTLI 
ALL-93 between October 1993 and September 1999. Twenty-five 
Brazilian institutions participated in the study. The diagnosis of 
ALL was based only on the morphological and cytochemistry 
features of the leukemic cells from bone marrow specimens. 
Immunophenotype and genetic features of the leukemic blasts 
were not required as obliged inclusion criteria, due to the 
lack of these exams in most Brazilian institutions at that time. 
Central morphological review was recommended. The protocol 
was approved by the Ethical Committee (IRB) of each of the 
25 participating institutions and written informed consent was 
obtained for each participant (patients or parents/guardians, as 
appropriate).
Initial risk classification was based on patient’s age and 
leukocyte count at baseline (National Cancer Institute Risk 
Group Criteria) and clinical extra medullary involvement of the 
disease. As previously mentioned, immunophenotyping, ploidy, 
the patients (817/853). Twenty-eight patients (3.4%) died during the induction phase. 
Thirty-four patients (4.0%) were lost to follow-up. The overall EFS was 66.1 ± 1.7% at 
15 years. No difference was seen according to maintenance: EFS15y was 65.8 ± 2.3% 
(group 1) and 66.3 ± 2.3% (group 2; p = 0.79). No difference between regimens was 
detected after stratifying the analyses according to factors associated with adverse 
prognosis in this study (age group <1 year or >10 years and high WBC at diagnosis). 
Overall death in remission rate was 6.85% (56 patients). Deaths during maintenance 
were 13 in group 1 and 12 in group 2, all due to infection. Over 15 years of follow-up, 
two patients both from group 2 presented a second malignancy (Hodgkin’s disease 
and thyroid carcinoma) after 8.3 and 11 years off therapy, respectively.
conclusion: Six-month reduction of maintenance therapy in ALL children treated 
according to the GBTLI ALL-93 protocol provided the same overall outcome as 2-year 
duration regimen.
Keywords: childhood acute lymphoblastic leukemia, maintenance all chemotherapy, pediatric all survival in 
middle-low-income countries
TaBle 1 | Therapy for very low-risk and low-risk all patients on gBTli 
all-93 protocol.
Phase length
Induction, first phase 4 weeks
Dexametasone 6 mg/m2/d orally × 28 days
Vincristin 1.5 mg/m2/dose IV (maximum 2 mg);  
days 1, 8, 15, and 22
Daunomycin 25 mg/m2/dose IV (1 h inf.); days 1, 8, 15, and 22
TITa at days 1 and 29
Induction, second phase 2 weeks
Each 2 days, start day 29
l-Asparaginase 10,000 IU/m2/dose IM (1 h inf.) × 8 doses
Cytarabine 75 mg/m2/d SC × 4 doses weekly; days 29–32 and 
40–43
TITa at day 43
Intensification 6 weeks
Each 2 weeks
Methotrexate 2 g/m2 IV (24 h inf.) with
LCV rescue 15 mg/m2/dose at hours 36, 42, 48, and 54
6-Mercaptopurine 50 mg/m2/d orally × 6 weeks
TITa each 2 weeks after systemic MTX infusion (×4)
Reinduction, first phase 4 weeks
Dexametasone 6 mg/m2/d orally × 21 days
Vincristin 1.5 mg/m2/dose IV (maximum 2 mg); days 106, 113, 
120, and 127
l-Asparaginase 10,000 IU/m2/dose IM × 4 doses; days 
106,109,113, and 116
TITa at day 106 and 126
Reinduction, second phase 2 weeks
6-Mercaptopurine 50 mg/m2/d orally × 14 days
Cytarabine 75 mg/m2/d SC × 4 doses weekly; days 134–137 
and 145–148
TITa at days 134, 141, and 148
Maintenance therapy randomization 18 or 24 
monthsGROUP 1 and GROUP 2
6-MP 50 mg/m2/d orally
MTX 25 mg/m2/dose IM weekly
TIT each 8 weeks
For low-risk group, pulses every 8 wk
DEXA 4 mg/m2 every other day × 3
VCR 1.5 mg/m2 IV (maximum 2 mg) at day 1
aDose according to age.
GBTLI, Brazilian Childhood Cooperative Group for ALL Treatment; ALL, acute 
lymphoblastic leukemia; TIT, triple intrathecal chemotherapy (methotrexate, cytarabine, 
and dexamethasone); IV, intravenous; IM, intramuscular; SC, subcutaneous; Inf., 
infusion; 6MP, 6-mercaptopurine; MTX, methotrexate; VCR, vincristine; LCV, leucovorin; 
d, day; h, hour; w/, with; wk, week.
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and cytogenetic were not considered as a risk variable in the 
study. Patient’s biological response was also not considered to 
define further risk stratification. Very low-risk group (VLR) was 
defined by age ≥1 and <10 years, with WBC ≤ 10,000/mm (3), 
no mediastinal mass or central nervous system (CNS) involve-
ment, and hepatosplenomegaly <5  cm below costal margin. 
Low-Risk Group (LR) was defined by age ≥1 and <10  years, 
WBC  >  10,000/mm3 and <50,000/mm3, and/or mediastinal 
mass, and/or hepatosplenomegaly ≥5  cm. High-Risk Group 
(HR) was defined by age <1 or ≥10 years, and/or WBC ≥ 50,000/
mm3, and/or CNS involvement at diagnosis. Complete clinical 
examination was routinely performed at the time of enrollment 
into the study.
Only 14 patients were excluded at diagnosis for the following 
reasons: acute myeloid leukemia (AML) diagnosis in 7 children 
and previous corticosteroid administration in other 7 patients. 
Of the 853 eligible patients, 421 were randomly allocated to 
receive 18  months (group 1) and 432 to receive 24-month 
(group 2) maintenance therapy. Randomization was performed 
at study enrollement by a central office. Fifteen children did not 
follow the randomized group due to medical misunderstanding: 
12 from the 18-month group and 3 from the 24-month group. 
It is important to emphasize that the overall treatment duration 
refers to the actual therapy received by the patient. Thirty-four 
patients were lost to follow-up (4.0%), being analyzed only till 
the abandonment time. For statistical analysis, abandonment was 
considered as an event.
Treatment schedule
Regimens were proposed according to the initially defined 
risk groups, as detailed in Tables  1 and 2. Briefly, VLR and 
LR group patients received Induction therapy (6  weeks) with 
dexamethasone (DEXA) 6  mg/m2/day  ×  28  days, Vincristine 
(VCR) 1.5 mg/m2/week × 4, Daunomycin 25 mg/m2/week × 4, 
l-Asparaginase 10,000  U/m2 IM  ×  8 and Ara-C 75  mg/m2/
dose × 8 and triple intrathecal therapy (TIT) with methotrexate 
(MTX)/Cytarabine (Ara-C)/DEXA (according to age) at days 0, 
29, and 43. Intensification phase (6 weeks) with MTX 2 g/m2 IV 
24 h infusion with leucovorin (LCV) rescue 15 mg/m2/dose × 4, 
6-Mercaptopurine (6-MP) 50 mg/m2/day × 6 weeks, and TIT × 4. 
Reinduction phase (6 weeks) with DEXA 6 mg/m2/day × 3 weeks, 
VCR 1.5  mg/m2/week ×  4, l-ASP 10,000  U/m2 IM ×  4, 6-MP 
50 mg/m2/day × 2 weeks, Ara-C 75 mg/m2/day SC × 8 days, and 
TIT × 3. Patients were centrally randomized to receive mainte-
nance therapy during 18 months (group 1) or 24 months (group 
2) with 6-MP 50mg/m2/day continuously, MTX 25 mg/m2/week 
IM, and TIT each 8 weeks during all maintenance. Pulses with one 
single dose of VCR 1.5 mg/m2 and DEXA 4 mg/m2/day × 7 days 
were done each 8 weeks only during the first year of the mainte-
nance treatment, for the LR Group of patients. Prophylactic CNS 
radiation was not performed in any LR.
Patients of the HR Group received the induction therapy, as for 
the low-risk patients, with additional high-dose Ara-C 750 mg/
m2 IV 3 h infusion each 12 h × 6 doses beginning at day 36, and 
l-ASP rescue at a dose of 6,000 U/m2 IM. Intensification phase was 
the same as for the low-risk group. Reinduction phase as for the 
low-risk group, except for the prophylactic CNS irradiation with 
18 Gy (CNS-1 and CNS-2 patients) or 24Gy (CNS-3 patients). 
Maintenance therapy with rotating blocks A, B, and C from week 
23 till week 77 (Block A = Ara-C 750 mg/m2 IV 3 h infusion each 
12 h × 6 doses and l-ASP 6,000 U IM/m2 6 h after the last Ara-C 
dose; Block B = DEXA 3 mg/m2/day × 21 days and VCR 1.0 mg/
m2/week × 3, and Block C = 6-MP 75 mg/m2/day × 3 weeks and 
MTX 40 mg/m2/week IM × 3). After week 77, patients received 
daily 6-MP 50  mg/m2 continuously and MTX 25  mg/m2/week 
IM and pulses of one single dose of VCR 1.5 mg/m2 and DEXA 
4 mg/m2/day × 7 were prescribed each 8 weeks, either until week 
103 (group 1) or week 130 (group 2). Full dose chemotherapy was 
recommended with WBC ≥ 2,000/mm3, total phagocytes ≥500/
mm3, and platelets counts ≥100,000/mm3.
TaBle 2 | Therapy for high risk all patients on gBTli all-93 protocol.
Phase length
Induction, first phase 4 weeks
Dexametasone 6 mg/m2/d orally × 28 days
Vincristin 1.5 mg/m2/dose IV (maximum 2 mg);  
days 1, 8, 15, and 22
Daunomycin 25 mg/m2/dose IV (1 h inf.); days 1, 8, 15, and 22
l-Asparaginase 10,000 IU/m2/dose IM (1 h inf.) × 8 doses;  
days 15–22
TITa at days 1, 15, and 29
Induction, second phase 2 weeks
Cytarabine 750 mg/m2/d IV (3 h inf.) each 12 h × 6 doses;  
days 36–38
l-Asparaginase rescue 6,000 IU/m2/dose IM × 6 doses at 
hour 6
TITa at day 43
Intensification 6 weeks
Each 2 weeks
Methotrexate 2 g/m2 IV (24 h inf.) with
LCV rescue 15 mg/m2/dose at hours 36, 42, 48, and 54
6-Mercaptopurine 50 mg/m2/d orally × 6 weeks
TITa each 2 week after systemic MTX infusion (×4)
Reinduction, first phase 4 weeks
Dexametasone 6 mg/m2/d orally × 21 days
Vincristin 1.5 mg/m2/dose IV weekly (maximum 2 mg); days  
106, 113, 120, and 127
l-Asparaginase 10,000 IU/m2/dose IM × 4 doses; days 
106,109,113, and 116
TITa at day 106 and 126
Reinduction, second phase 2 weeks
6-Mercaptopurine 50 mg/m2/d orally × 14 days
Cytarabine 75 mg/m2/d SC × 4 doses weekly; days  
134–137 and 145–148
TITa at days 134, 141, and 148
CNS RTa
Maintenance therapy, first phase (weeks 23–77) 18 or 
24 monthsBlock A (6 blocks) weeks 23, 32, 41, 50, 59, and 68
Cytarabine 750 mg/m2/d IV (3 h inf.) each 12 h × 6 doses; 
days 36–38
l-Asparaginase rescue 6,000 IU/m2/dose IM × 6 doses 
at hour 6
Block B
DEXA 3 mg/m2/d orally × 21 days
VCR 1 mg/m2 IV (maximum 2 mg) at days 1,8, and 15
Block C
6-MP 75 mg/m2/d orally × 21 days
MTX 40 mg/m2/dose IM; days 1, 8, and 15
Maintenance therapy, second phase 
Pulses every 8 wk (start week 77 until the week 103, for 
group 1 or the week 130, for group 2)
DEXA 4 mg/m2/d orally × 7 days
VCR 1.5 mg/m2 IV (maximum 2 mg) at day 1
6-MP 50 mg/m2/d orally
MTX 25 mg/m2/dose IM weekly
TITa each 8 weeks, except for CNS radiated patients
aDose according to age.
GBTLI, Brazilian Childhood Cooperative Group for ALL Treatment; ALL, acute 
lymphoblastic leukemia; TIT, triple intrathecal chemotherapy (methotrexate, 
cytarabine, dexamethasone); IV, intravenous; IM, intramuscular; SC, subcutaneous; 
Inf., infusion; 6MP, 6-mercaptopurine; MTX, methotrexate; VCR, vincristine; 
LCV, leucovorin; d, day; h, hour; w/, with; wk, week; CNS, central nervous system; 
RT, radiation therapy.
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It is important to emphasize that the overall treatment dura-
tion refers to the actual therapy received by the patient. Periods 
without programed chemotherapy were compensated.
sTaTisTical analYsis
Kaplan–Meier curves were used to illustrate children’s overall 
or EFS, and log rank tests to compare the curves for distinct 
groups of children. Overall survival (OS) was defined as the time 
period from diagnosis to death. EFS was defined as the time from 
diagnosis of ALL until the date of either induction failure, relapse, 
death in remission from any cause, the development of a second 
cancer, or until the date of last contact for all event-free survivors. 
Thirty-four patients (4.0%) were lost to follow-up: 12 children 
who were lost of follow-up after cessation of therapy (5.3 years of 
mean EFS), 9 during the maintenance phase (mean EFS 0.3 years), 
and 2 without reaching remission (EFS = 0). Maintenance EFS 
(M-EFS) was defined as the time from the beginning of the main-
tenance phase to relapse or death. Comparison between groups 
was done based on the intention-to-treat. The significance level 
was set at p ≤ 0.05. Statistical analyses were performed with the 
SPSS 20.0 software (SPSS Inc., Chicago, IL, USA) on the basis of 
data obtained up to June, 2016.
resUlTs
From October 1993 to September 1999, 867 consecutive patients 
from 25 Brazilian Institutions entered the study. Only 14 patients 
(1.6%) were excluded from the analysis for the following reasons: 
AML diagnosis (7 patients) and previous corticosteroid use (7 
patients). In total, 853 patients were analyzed, being 406 of them 
classified as HR (48%). Clinical and laboratorial data are listed 
in Table 3. After induction therapy, 817 children (96%) achieved 
clinical complete remission (CCR). Thirty-six patients (4%) had 
induction failure. Twenty-eight children died during this initial 
phase (3.4%), mainly due to infections. Thirty-four patients 
(4.0%) were lost to follow-up. The mean time of follow-up for 
children without an event was 12.8  years (interquartile range: 
5.7  years). Any event was registered in 285 patients. For these 
children, the median time to an event was 1.9 years (interquartile 
range 2.6 years). Clinical outcomes are summarized in Tables 4 
and 5. Over 15 years of follow-up, 2 patients both from group 2 
presented a second malignancy (Hodgkin’s disease and thyroid 
carcinoma) after 8.3 and 11 years of therapy, respectively.
The long-term 15-year OS was 70.0 ± 1.6% (Figure 1A). The 
overall EFS rate was 66.1 ± 1.7% (Figure 1B). No difference was 
detected according to the two maintenance regimens: group 1 
(18-month duration) with pEFS15y =  65.8 ±  2.3% and group 2 
(24-month duration) with pEFS15y  =  66.3  ±  2.3% (p  =  0.79; 
Figure  1C). Furthermore, even after stratifying the analyses 
according to the risk groups, there were no statistically significant 
differences in the EFS of group 1 vs. group 2, either among the 
very low and low-risk patients (p =  0.33), or among high-risk 
patients (p = 0.62). The same observation holds true relatively to 
gender (p = 0.60 and p = 0.87 for males and females, respectively), 
to age group (<1 year, ≥1 < 10 years, and ≥10 years), and WBC 
at diagnosis (< or ≥50,000/mm3). If only children who started 
TaBle 4 | clinical outcomes of 853 all patients treated according to 
gBTli all-93 protocol.
no. of cases %
Total number of analyzed patients 853 100
Attained remission at the end of induction 817 96
Induction failure (include induction deaths) 36 4
In CCR 590 69.1
Blast D8 (/mm3)
<1,000 751 88.0
≥1,000 39 4.6
Not performed 63
WBC D8 (/mm3)
<10,000 766 89.8
≥10,000 and <50,000 23 2.7
≥50,000 and <100,000 3 0.3
≥100,000 0
Not performed 61
Site of relapses
BM 138 16.1
CNS 12 1.4
Others 6 0.7
Combined 15 1.7
Death
In induction 28 3.3
In remission 56 6.7
After relapse 154 18.0
Not remission 6 0.7
After BMT 1 0.1
Lost of follow-up 34 4.0
Mean of follow-up 9.1 years
TaBle 3 | clinical and laboratorial data of 853 patients with all treated 
with gBTli all-93 protocol.
no. of cases %
Registered patients 867 100
Excluded patients 14 1.6
AML diagnosis 7
Previous corticosteroids use 7
Total of analyzed patients 853 98.4
White 627 73.5
Non-white 226 26.5
Age (in years)
<1 23 2.7
≥1 to <10 636 74.6
≥10 194 22.7
Gender
Male 437 51.2
Female 416 48.7
WBC (/mm3)
<10,000 378 44.3
≥10,000 to <50,000 252 29.5
≥50,000 to <100,000 94 11.0
≥100,000 129 15.1
Risk group
Very low risk 154 18.0
Low risk 293 34.3
High risk 406 47.6
CNS involvement at Dx 23 2.7
Testis involvement at Dx 8 0.9
Immunophenotype test
T-ALL 76 12.8
B-ALL 517 87.2
Not performed 197
Not referred 63
Calla antigen (CD10) positive 475 85.3
Calla antigen (CD10) negative 82 14.7
Not performed 296
Cytogenetic
Exam performed 57 6.7
Normal 27 47.4
Hyperdiploidy 11 19.3
Hypodiploid 3 5.3
Not attained metaphases 16 28.0
Not performed 796 93.3
Molecular biology
Exam performed 91 10.6
Chromos without abnormalities analyzed 66 72.5
Chromos abnormalities 25 37.8
t (12; 21) 15
t (1; 19) 5
t (4; 11) 1
t (9; 22) 4
Not performed 762 89.3
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the maintenance phase were considered (n  =  760, 373 from 
18-month group, and 387 from the 24-month group), excluding 
those who relapsed or died before it, the M-EFS was 74.3 ± 2.3% 
for group 1 and 74.0 ± 2.3% for group 2 (p = 0.99; Figure 1D).
The overall death in remission rate was 6.8% (56 patients). 
Importantly, of the 25 deaths that happened during the 
maintenance phase, 13 were from group 1 and 12 from group 2, 
all of them due to infections.
According to the protocol risk group, the pEFS15yr was 
78.7 ± 3.4% (VLR group, n = 154), 76.5 ± 2.6% (LR, n = 293), 
and 53.8 ± 2.5% (HR Group, n = 406) (Figure 2A, p < 0.0001). 
According to age, children <1-year-old (n = 23) had a pEFS15yr 
of 30.4 ± 9.6%; those >10-year-old (n = 194) had a pEFS15y of 
55.4 ± 3.6%, and those ≥1 and <10 years of age (n = 636) had a 
pEFS15yr of 70.65 ± 1.8% (Figure 2B, p < 0.0001). Patients with 
initial WBC counts ≤10,000/mm3 (n = 378) had better pEFS15yr 
rates as compared to those with ≥100,000/mm3 (n  =  129): 
72.1 ± 2.4 vs. 52.7 ± 4.4%, respectively (Figure 2C, p < 0.0001).
Only 593 patients (69.5%) had immunophenotypic analysis 
performed at diagnosis: 12.8% were T-cell ALL (n = 76), 7.4% were 
pre-B CD10 negative (n = 44), and 79.8% pre-B CD10 positive 
(n = 473). The pEFS15yr for these three groups were 46.0 ± 5.7%, 
47.5 ±  7.6%, and 73.1 ±  2.1%, respectively (p <  0.0001). Only 
57 patients (6.7%) had cytogenetic and 91 patients (10.7%) had 
molecular biology studies performed.
Even though initial response to therapy was not used for further 
children’s allocation into the risk groups, patients with peripheral 
WBC counts <10,000/mm3 at day 8 (D8) (n = 766) had long-term 
EFS of 68.2 ± 1.7%, while for those with ≥10,000/mm3 (n = 26) 
the EFS was 34.6  ±  9.3% (p  <  0.0001) (Figure  3A). Similar 
results were observed in patients with D8 WBC <  5,000/mm3 
(n = 703) when compared to those with ≥5,000/mm3 (n = 89): 
EFS = 69.3 ± 1.8 vs. 49.3 ± 5.3%, respectively (p < 0.0001). In 
TaBle 5 | Treatment results according to clinical and laboratorial data of 
853 all patients treated with the gBTli all-93 protocol.
eFs at 
15 years
95% confidence 
interval
p Value
Sex
Male 437 0.662 0.617–0.707 0.98
Female 416 0.659 0.612–0.706
Age
<1 year 23 0.304 0.116–0.492 <0.00001
≥1 to <10 years 636 0.706 0.670–0.743
≥10 years 194 0.554 0.483–0.624
WBC ( ×109/L)
<10 × 109/L 378 0.721 0.674–0.768 <0.00001
10−50 × 109/L 252 0.676 0.617–0.734
50−100 × 109/L 94 0.563 0.463–0.664
≥100 × 109/L 129 0.527 0.440–0.612
WBC (×109/L)
<50 × 109/L 630 0.703 0.666–0.740 <0.00001
≥50 × 109/L 223 0.542 0.477–0.607
Immunophenotypea
Pre-B CD10 positive 473 0.731 0.690–0.772 <0.00001
Pre-B CD10 negative 44 0.475 0.327–0.623
T-cell 76 0.460 0.348–0.572
NCI risk groups
Standard risk 447 0.773 0.732–0.814 <0.00001
High risk 406 0.538 0.489–0.587
GBTLI risk group
Very low risk 154 0.787 0.721–0.853 <0.00001
Low risk 293 0.765 0.715–0.816
High risk 406 0.538 0.489–0.587
CNS statusa
Positive 23 0.566 0.364–0.768 0.17
Negative 830 0.668 0.635–0.701
Testicular involvement
Yes 8 0.750 0.450–1.000 0.75
No 429 0.660 0.615–0.705
Mediastinal involvement
Yes 54 0.572 0.439–0.705 0.08
No 799 0.667 0.634–0.700
D8 peripheral WBCa
<5 × 109/L 703 0.693 0.658–0.728 <0.00001
≥5 × 109/L 89 0.493 0.389–0.597
D8 peripheral blasta
Positive 182 0.531 0.457–0.605 <0.00001
Negative 608 0.713 0.676–0.750
aThere are missing values for some children.
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addition, patients with any peripheral blasts at D8 (n =  182) 
had a worse prognosis than those with negative blasts (n = 608; 
p < 0.0001). Combined analysis revealed that patients with D8 
WBC ≥ 5,000/mm3 and any blasts at D8 had a significantly poorer 
pEFS15yr than patients with D8 WBC < 5,000/mm3 and no blast at 
D8 (p < 0.0001) (Figure 3B).
DiscUssiOn
The GBTLI started the first trial in 1980. Consecutive studies 
ALL-82 and ALL-85 contributed to significant improvement of 
the survival cure rates for the Brazilian children and adolescents 
up to 70 ± 4% of EFS (11). Results here presented for the GBTLI 
ALL-93 (EFS15y = 66.1 ± 1.7%) are comparable to both our earlier 
results (GBTLI ALL-85) and those obtained in other prospective 
treatment protocols for childhood ALL conducted by interna-
tional cooperative groups in HICs over a similar period of time 
(1981–2000): UKALLX1 (EFS5yr = 63.1 ± 2.2%) (12), COALL-92 
(EFS5yr = 76.9 ± 1.9%) (13), DCLSG-ALL-8 (EFS5yr = 73 ± 2%) 
(14), EORTC-CLG 58881 (EFS5yr = 70.9 ± 1.1%) (15), NOPHO 
ALL92 (EFS5yr = 77.6 ± 1.4%) (16), BFM-95 ALL (EFS5y = 79.6%) 
(17, 18), and AIEOP-95 (EFS5y = 75.9%) (19).
It is difficult to compare the GBTLI ALL-93 protocol results 
with other contemporary published reports from the literature, 
considering that those studies included different ages, clinical, 
and laboratorial (immunophenotyping, cytogenetic, and ploidy) 
criteria for the group risk definitions. At that time, only age, WBC, 
and clinical extra medullary involvement of the disease were 
defined as risk criteria in our studies. Brief reports of our results 
have already been presented (20). Additionally, it is known that 
racial, nutritional, and socioeconomic variables also influence the 
survival of pediatric patients with acute leukemia (21–24).
Survival for children and adolescents with ALL has improved 
over time due to more precise risk classification and refinement of 
post-induction therapy through serial clinical trials (25). As one 
induction intensification and one or two consolidation therapies 
have improved cure rates of this disease, the necessity of several 
years of maintenance therapy has been recently questioned (5). 
As already mentioned, a systematic review of several randomized 
studies on childhood ALL, indicates that longer maintenance 
therapy did not improve survival because the somewhat lower 
risk of relapse was counterweighed by a higher risk of death 
in remission (10). Furthermore, longer as well as higher 6MP/
MTX doses have, in three recent studies, been associated with 
an increased risk of second malignancies (6, 7, 26). In the GBTLI 
ALL-93 study, two second malignancies were registered in chil-
dren from group 2 (24-month maintenance).
The long-term clinical results of the GBTLI ALL-93 protocol 
showed that it was feasible to shorten to only 18  months, the 
maintenance therapy for ALL patients, in the Brazilian setting. It 
remains to be seen if the modern protocols that reached survival 
rates above 85% depend upon the duration of the maintenance 
therapy. The lower survival rate in our study was mainly due 
to induction mortality and death in remission, predominantly, 
because of infections. Also, it is important to emphasize that in 
order to “overcome” the lack of diagnostic tools, the post-induc-
tion therapy was much more aggressive for the high-risk patients 
of the study, mainly because the high-dose Ara-C (750 mg/m2 × 6 
doses) starting on day 36, shortly after obtaining the remission. 
Twenty-three patients died before attaining the maintenance 
period, 17 of them belonging to the HR.
Whether these patients who died due to toxicity and/or 
infections would benefit from a longer maintenance, has yet to 
be addressed. However, the fact that the next GBTLI ALL-99 
protocol has already adopted the shorter maintenance therapy 
(18-month duration) with reasonable survival rates (27) allows 
us to suggest that such reduction may generally be advantageous 
for the patients. In our experience, there is no clear benefit to 
prolong this phase, neither considering the gender nor the NCI 
FigUre 1 | long-term survival of 853 all-children treated by gBTli all-93 protocol: (a) overall survival, (B) event-free survival, (c) eFs according 
to maintenance regimen length, (D) M-eFs according to maintenance regimen length.
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risk criteria at diagnosis. The possibility to decrease in 6 months, 
the treatment duration, contributes to more days at school, less 
expenditure with transportation to the clinics, and probably bet-
ter quality of life. However, there is evidence that shortening the 
maintenance therapy too much may be risky. A previous study 
that shortened the total protocol duration from 2 to 1.5 years, sig-
nificantly reduced the EFS. When all chemotherapy was limited 
to 52 weeks from diagnosis, the pEFS5y was as low as 60%, even 
for non-high-risk ALL patients (28).
Even though early response evaluation to induction therapy 
was not used for patient’s stratification, D8 peripheral WBC 
counts were routinely recorded in the present study. Peripheral 
blast count reduction is well established by different investigators 
as a prognostic factor (17, 29). The GBTLI ALL-93 protocol pro-
posed the simple WBC counts at D8 of treatment, as a predictor 
for therapy failure, based on previous data from our group show-
ing that WBC counts were highly predictive of outcome (19, 30). 
The present study validated these earlier findings by showing that 
patients with either D8 peripheral WBC > 5,000 leukocytes/mm3 
or the presence of any blast in D8 peripheral blood had adverse 
prognosis. Persistence of circulating blasts in peripheral blood at 
D8 after multi-agent chemotherapy in individual ALL patients 
had been previously reported as a poor prognostic factor with a 
relative risk of 2.9 (p < 0.0001) (31).
The rational of the study GBTLI ALL-93 was that shorten-
ing the maintenance therapy could increase survival both by 
reducing the immunosuppressive period and improving patient 
adherence. However, death in the maintenance phase was equally 
distributed between the two groups. Despite socioeconomic 
difficulties in Brazil at that time, only 4.0% of the patients were 
lost to follow-up. Lack of adherence to oral chemotherapy has 
been reported in children with ALL (32, 33), that was the reason 
to maintain, in this study, the MTX by IM route during all the 
maintenance therapy. Facilitators and barriers to adherence were 
not analyzed as part of the GBTLI ALL-93 study.
The GBTLI ALL-93 study offered a unique opportunity 
to address ALL treatment in the context of restricted access 
to modern technologies. Therapeutic strategies capable of 
FigUre 2 | event-free survival of 853 all-children treated by gBTli all-93 protocol: (a) according to the protocol risk factors, (B) according to age 
at diagnosis, (c) according to WBc count at diagnosis.
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overcoming these limitations in low- and middle-income coun-
tries remain an important topic to be investigated in the future, 
with controlled prospective studies performed in those parts of 
the world.
Unfortunately, recent national published data reveal a 5-year 
OS of only 47% for children with ALL living in different regions of 
Brazil. Those rates have not changed for a period of three decades 
(1996–2008) (34–36). Similarly, national published data from 
1996 to 2008, covering different geographical regions of Brazil, 
reveal no changes in mortality rates due to leukemia in patients 
with <20 years of age. Surprisingly, differences between the rich 
and poor geographic areas of the country are lower than 2% (34). 
It is noteworthy that the survival rates of children with ALL living 
in the Rio Grande do Sul State reached EFS5y = 62.41 ± 2.43% 
when treated with the GBTLI ALL protocols, while patients 
not included in any study had EFS5y  =  49.47  ±  4.15% (37). 
Unfortunately, less than 1% of the estimated new ALL patients 
with <18 years are registered in the GBTLI.
In 2015, there were 187 centers in Brazil registered at the 
Health Ministry for the care of children with cancer. Only 67 
institutions were accredited for pediatric oncology care (38). 
How could children’s mortality rates due to cancer be reduced 
in low- and middle- income countries? Probably by: (1) limiting 
the number of specialized centers to deliver pediatric cancer 
treatment, (2) reinforcing and promoting institutional participa-
tion in cooperative prospective protocols with an overarching 
and monitoring structure, and (3) establishing a national health 
policy for accreditation and governance of childhood cancer 
treatment centers (3).
cOnclUsiOn
Within the GBTLI ALL-93 protocol, the length of maintenance 
therapy could be safely abbreviated to 18  months, indepen-
dently of the patient’s gender and risk group defined by age, 
WBC counts, and clinical extramedullary ALL involvement at 
FigUre 3 | event-free survival of 853 all-children treated by gBTli all-93 protocol related to initial induction therapy response (at D8): (a) 
according to peripheral WBc counts, (B) according to the presence of any blast and WBc counts.
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diagnosis. It was feasible to achieve in Brazil long-term OS rates 
of 70% for children with ALL, corroborating the value of national 
prospective cooperative studies. The possibility of decreasing the 
maintenance treatment by 6 months may contribute to overcome 
major financial and cultural obstacles, remaining as adverse situ-
ations in middle- and low-income countries.
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